Therapeutic Asset Ratings

464 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pelareorep Breast Carcinoma	Mridula George, MD	P2	CCC (53)
Pelareorep mCRC	Oncolytics Biotech	P2	CCC (53)
Pelareorep Triple-Negative Breast Carcinoma	Mridula George, MD	P2	CCC (53)
Pelareorep MSS Metastatic Colorectal Cancer	Oncolytics Biotech	P2	CCC (53)
Pelareorep Metastatic Malignant Neoplasm In The Colon	Oncolytics Biotech	P2	CCC (53)
Plencifgene Parvec Cystic Fibrosis	4D Molecular Therapeutics	P2	CCC (53)
Recombinant Human Adenovirus Type 5 Portal Vein Thrombosis	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Recombinant Human Il-21-Expressing Oncolytic Vaccinia Virus Malignant Pancreatic Neoplasm	Hangzhou Converd Co., Ltd.	P2	CCC (53)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Nonpapillary Renal Cell Carcinoma	Mayo Clinic	P2	CCC (53)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Renal Cell Carcinoma	Mayo Clinic	P2	CCC (53)
Sleeping Beauty Transposed Pbl Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Sleeping Beauty Transposed Pbl Gastrointestinal/Genitourinary Cancers	National Cancer Institute (NCI)	P2	CCC (53)
Bbm-P002 Parkinson Disease	Shanghai Xinzhi BioMed Co., Ltd.	P1	CCC (53)
Olvimulogene Nanivacirepvec Fallopian Tube Cancer	Genelux Corporation	P3	CCC (52)
Autologous Cd34+ Hsc Cells Transduced With The Lentiviral Vector Containing A Shrna Targeting Bcl11A Sickle Cell Disease	David Williams	P2	CCC (52)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells HIV Infectious Disease	AIDS Malignancy Consortium	P1/2	CCC (52)
Quaratusugene Ozeplasmid Non-Small Cell Lung Carcinoma	Genprex, Inc.	P1/2	CCC (52)
Spk-8016 Hemophilia A	Spark Therapeutics, Inc.	P1/2	CCC (52)
PF-06939926 IS A RECOMBINANT AAV VECTOR CONTAINING THE AAV SEROTYPE 9 (AAV9) CAPSID PACKAGING A MINIATURIZED CODON-OPTIMIZED VERSION OF THE DMD GENE(CALLED OPTI-DYS.DELTA.3978) WHICH ENCODES THE DOMAINS MINIMALLY REQUIRED FOR FUNCTIONALITY OF THE DYSTROPHIN PROTEIN (MINI-DYSTROPHIN). A SYNTHETIC POLYADENYLATION (SPOLYA) SEQUENCE FOLLOWS THE OPTI-DYS.DELTA.3978 GENE. CARDIAC AND SKELETAL MUSCLE-SPECIFIC TRANSGENE EXPRESSION IS MEDIATED BY A SYNTHETIC ENHANCER AND PROMOTER. THE EXPRESSION CONSTRUCT IS FLANKED BY THE AAV2 INVERTED TERMINAL REPEATS (ITRS). THE 3978 BASEPAIR MINI-DYSTROPHIN OPEN READING FRAME ENCODES THE N-TERMINUSHINGE REGIONS H1, H3 AND H4SPECTRIN-LIKE REPEATS R1, R2 AND R22-24AND THE C-TERMINAL CYSTEINE-RICH REGION OF THE DYSTROPHIN PROTEIN. Duchenne Muscular Dystrophy	Pfizer	P3	CCC (51)
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101) Rectum Adenocarcinoma	Chongqing University Cancer Hospital	P2	CCC (51)
Recombinant Human Adenovirus Type 5 Liver Metastases	Fujian Cancer Hospital	P2	CCC (51)
Adv/Hsv-Tk Glioblastoma	The Methodist Hospital Research Institute	P1/2	CCC (51)
Recombinant Human Adenovirus Type 5 Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P2	CCC (50)
ISARALGAGENE CIVAPARVOVEC Fabry Disease	Sangamo Therapeutics	P1/2	CCC (50)
m032 Glioblastoma	University of Alabama at Birmingham	P1/2	CCC (50)

Showing 126 to 150 of 464 assets

PreviousPage 6 of 19Next